Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2014

View Archived Issues

Voyant Biotherapeutics and Allergan enter R&D agreement in ocular disease

German group patents novel antibodies for Plasmodium infections

Unbiased screening of chemotherapeutic agents used to uncover novel indications for existing drugs

Japanese researchers present new agents for neurological disorders and cancer

Discovery of a novel variant in a gene of unknown function associated with fatty liver disease

SCY-078 receives QIDP designation from the FDA

EMA concludes review of Protelos/Osseor

Novel FGFR inhibitors disclosed by Incyte Corp.

Scientists at Boehringer Ingelheim divulge novel BTK inhibitors

Janssen begins phase III CREDENCE study of canagliflozin in diabetic nephropathy

New vasopressin V1b receptor antagonists patented by Japanese group

Isis Pharmaceuticals reports data on ISIS-SMNRx in children with spinal muscular atrophy

Bristol-Myers Squibb discloses new agents for HIV infection

Cathepsin G detrimental in a subset of mice with ischemic stroke

Emergent BioSolutions' acquisition of Cangene complete

New phase Ib study evaluates ONT-380 with Kadcyla in metastatic HER2-positive breast cancer

Tender offer for NuPathe shares completed by Teva Pharmaceutical

FDA extends PDUFA action date for Ruconest

FDA extends approval of Kalydeco for cystic fibrosis mutations

Dosing completed in phase II trial of GCS-100 for chronic kidney disease

FDA grants 3-year exclusivity to Vascepa

Jazz Pharmaceuticals completes tender offer for Gentium shares

FTY-720 show anti-inflammatory effects on cerebral ischemia-reperfusion in vivo

Intra-arterial verapamil demonstrates neuroprotective properties in ischemic stroke model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...